Meet
Gina Krupp

Senior Associate

Gina Krupp supports clients with research and analysis that span a variety of healthcare sectors and stakeholders.

She applies her background in health policy and management to a diverse range of client projects.

Before joining Avalere, Gina worked as a policy fellow at the Global Healthy Living Foundation. There, she supported policy analysis on legislation impacting chronic disease patient populations, including legislation affecting medication affordability and access, particularly for biologics and biosimilars. Gina has also contributed to public health research, studying how healthcare disruptions from COVID-19 impacted type two diabetes management and health outcomes. 

Gina has an MPH in health policy and management from Columbia University and a BA in global health and gender studies from Northwestern University.

Authored Content


Community oncology networks are growing in size and influence. Five trends are poised to reshape how these networks deliver care, make decisions, and engage stakeholders.

This paper details five AMP increase scenarios that could lead to a generic manufacturer being subject to inflation rebates in situations where the generic manufacturer is not taking a price increase beyond the inflation rate.

Overall coverage of MS drugs among Part D plans declined by six percentage points, from 49% of the time across all plans and drugs analyzed in 2024 to 43% in 2025.

Physicians could lose at least $25 billion in add-on payments for 10 Part B drugs expected to be negotiated by CMS, with oncology products accounting for at least $12 billion.

Sixty-nine percent of 340B contract pharmacies were associated with a PBM through vertical integration (53%) or contractual arrangement (16%).

In 2023, 54% of Medicare Advantage enrollees were in plans that required step therapy for 10 commonly used rheumatoid arthritis drugs covered under Part B.

The Hospital Insurance Trust Fund would remain solvent until 2048 if FFS utilization levels were similar to Medicare Advantage utilization levels.

The CMMI’s EOM began on July 1 with 44 participants. A recent OCM evaluation report described net losses to CMS and lessons that can be applied to EOM.

Beneficiary interviews show the importance of Medicare Plan Finder as a resource and generated ideas to incorporate IRA reforms and improve user experience.

Forty-four Part B drugs could be subject to new CMS wastage refund requirements according to an Avalere analysis of Medicare claims.